Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Jun
16
Today In Oncology
Metastatic Colorectal Cancer GUCY2C-Targeted CAR T-Cell Therapy
Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo